Surufatinib for advanced neuroendocrine tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests the drug surufatinib in people with advanced neuroendocrine tumors. It is a real-world study, meaning it looks at how the drug works in everyday practice, and may help control tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of neuroendocrine neoplasm (a type of tumor that can grow in hormone-making cells).
- Your tumor must be measurable on a scan (like a CT or MRI).
- Your organs and bone marrow must be working well enough for treatment.
- You must be expected to live at least 12 more weeks.
- You cannot have other active cancers (except for certain skin, cervical, or breast cancers treated fully).
- You cannot have active bleeding, ulcers, uncontrolled high blood pressure, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (Surufatinib) and chemotherapy (Temozolomide and S-1) as a first treatment for advanced neuroendocrine tumors that have not been treated before. It aims to see if this drug combo is safe and effective.
This trial tests a combination of targeted therapy (surufatinib), immunotherapy (serplulimab), and standard chemotherapy as a first treatment for advanced solid tumors that have neuroendocrine features. It aims to see if this combination can shrink tumors and improve outcomes for patients with certain cancers.
This trial tests whether the drug Surufatinib, given before surgery, can shrink locally advanced or metastatic thyroid cancer. It's a targeted therapy that blocks blood vessels that feed tumors, and is given as a pill to see if it makes the cancer easier to remove.
This Phase 2 study tests whether adding surufatinib to first-line treatment (either AG or a similar AG-based regimen) can improve outcomes for people with locally advanced or metastatic pancreatic cancer. You may be considered if your cancer cannot be removed by surgery and you’ve already had a short course of similar treatment with a response.
The purpose of this study is to see how well the medication surufatinib works and how safe it is for people with neuroendocrine tumours. They want to gather more information from a real-world setting to understand the benefits and side effects of this treatment.
This trial tests whether adding chemotherapy to the drug surufatinib works better than surufatinib alone for people with a rare type of lung cancer called pulmonary neuroendocrine tumor. If you have this diagnosis and haven't had prior systemic treatment, you may be eligible.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.